看多
$ARQL Highly unusual BULLISH upside options activity
When the options market explodes with call buying in a stock it is a pretty good sign something is on the way. In the NASDAQ:ARQL options market the $10 call strike expiry July 19th have seen up to 400% higher volume than normal. That is significant as earnings are not due until August, so there must be another stimulus on the way. Keep on the watchlist.
AVERAGE ANALYSTS PRICE TARGET $8.54
AVERAGE RECOMMENDATION BUY
SHORT INTEREST 8.7%
COMPANY PROFILE
ArQule, Inc. is a biopharmaceutical company, which engages in the research and development of therapeutics to treat cancers and rare diseases. The company discovers, develops and commercializes novel small molecule drugs in areas of unmet need that will dramatically extend and improve the lives of its patients. Its proprietary pipeline includes ARQ 531, Derazantinib, Miransertib, ARQ 751 and Derazantinib products.
AVERAGE ANALYSTS PRICE TARGET $8.54
AVERAGE RECOMMENDATION BUY
SHORT INTEREST 8.7%
COMPANY PROFILE
ArQule, Inc. is a biopharmaceutical company, which engages in the research and development of therapeutics to treat cancers and rare diseases. The company discovers, develops and commercializes novel small molecule drugs in areas of unmet need that will dramatically extend and improve the lives of its patients. Its proprietary pipeline includes ARQ 531, Derazantinib, Miransertib, ARQ 751 and Derazantinib products.
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。